NI200800017A - Formas cristalinas de la 4- metil-n-[3-(4- metil- imidazol-1-il)-5- trifluoro- metil-fenil]-3- (4- piridin- 3- il- pirimidin- 2-il -amino) benzamida - Google Patents

Formas cristalinas de la 4- metil-n-[3-(4- metil- imidazol-1-il)-5- trifluoro- metil-fenil]-3- (4- piridin- 3- il- pirimidin- 2-il -amino) benzamida

Info

Publication number
NI200800017A
NI200800017A NI200800017A NI200800017A NI200800017A NI 200800017 A NI200800017 A NI 200800017A NI 200800017 A NI200800017 A NI 200800017A NI 200800017 A NI200800017 A NI 200800017A NI 200800017 A NI200800017 A NI 200800017A
Authority
NI
Nicaragua
Prior art keywords
methyl
imidazol
trifluoro
phenyl
amino
Prior art date
Application number
NI200800017A
Other languages
English (en)
Spanish (es)
Inventor
W Manley Paul
Shieh Wen-Chung
Allen Sutton Paul
H Karpinski Piotr
Wu Raeann
Monnier Stephanie
Brozio Joerg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37451227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI200800017(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NI200800017A publication Critical patent/NI200800017A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NI200800017A 2005-07-20 2006-07-18 Formas cristalinas de la 4- metil-n-[3-(4- metil- imidazol-1-il)-5- trifluoro- metil-fenil]-3- (4- piridin- 3- il- pirimidin- 2-il -amino) benzamida NI200800017A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70140505P 2005-07-20 2005-07-20
US71621405P 2005-09-12 2005-09-12

Publications (1)

Publication Number Publication Date
NI200800017A true NI200800017A (es) 2009-03-03

Family

ID=37451227

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200800017A NI200800017A (es) 2005-07-20 2006-07-18 Formas cristalinas de la 4- metil-n-[3-(4- metil- imidazol-1-il)-5- trifluoro- metil-fenil]-3- (4- piridin- 3- il- pirimidin- 2-il -amino) benzamida

Country Status (42)

Country Link
US (4) US8343984B2 (enExample)
EP (5) EP1912973B1 (enExample)
JP (3) JP5289948B2 (enExample)
KR (3) KR20130077915A (enExample)
CN (2) CN102358736A (enExample)
AR (1) AR054846A1 (enExample)
AU (3) AU2006276204A1 (enExample)
BR (1) BRPI0613615B1 (enExample)
CA (1) CA2614334C (enExample)
CR (1) CR9657A (enExample)
CU (1) CU23916B1 (enExample)
CY (2) CY1113076T1 (enExample)
DK (2) DK2284167T4 (enExample)
EA (2) EA016856B1 (enExample)
EC (1) ECSP088119A (enExample)
ES (3) ES2648288T3 (enExample)
GE (1) GEP20115302B (enExample)
GT (1) GT200600315A (enExample)
HN (1) HN2008000311A (enExample)
HR (2) HRP20120573T1 (enExample)
HU (1) HUE031791T2 (enExample)
IL (2) IL188189A0 (enExample)
JO (1) JO3308B1 (enExample)
LT (1) LT2284167T (enExample)
MA (1) MA29626B1 (enExample)
MX (1) MX2008000899A (enExample)
MY (1) MY148554A (enExample)
NI (1) NI200800017A (enExample)
NO (1) NO341930B1 (enExample)
NZ (1) NZ564409A (enExample)
PE (1) PE20070214A1 (enExample)
PH (1) PH12013501590A1 (enExample)
PL (2) PL1912973T3 (enExample)
PT (2) PT1912973E (enExample)
RS (1) RS55929B2 (enExample)
SG (1) SG163620A1 (enExample)
SI (2) SI2284167T2 (enExample)
SM (1) SMP200800011B (enExample)
TN (1) TNSN08029A1 (enExample)
TW (1) TWI406661B (enExample)
UA (1) UA94234C2 (enExample)
WO (1) WO2007015870A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
AU2007235976A1 (en) * 2006-04-07 2007-10-18 Novartis Ag Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
EP2240172B1 (en) 2007-12-21 2014-03-19 Novartis AG Combination of nilotinib and chlorambucil for the treatment of chronic lymphocytic leukemia
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
US8227477B2 (en) * 2008-11-05 2012-07-24 Greta Sterimbaum Nilotinib HCl crystalline forms
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
WO2010100248A1 (en) 2009-03-06 2010-09-10 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak)
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
MX2012004709A (es) 2009-10-23 2012-05-23 Novartis Ag Metodo para el tratamiento de transtornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r.
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2010KO00035A (enExample) * 2010-01-15 2016-09-02
JP2013525296A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー 内分泌療法抵抗性乳癌の処置
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
ES2555263T3 (es) 2010-06-21 2015-12-30 Teva Pharmaceutical Industries Ltd. Sales de Nilotinib y formas cristalinas de las mismas
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
IN2010CH03577A (enExample) * 2010-11-26 2012-07-20 Hetero Research Foundation
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013063000A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
MX2014005874A (es) 2011-11-14 2014-06-23 Novartis Ag Formulacion de liberacion inmediata de 4 - metil - 3 - [ [4- (3-piridinil) - 2 - pirimidinil] - amino] - n - [5 - (4 - metil - 1h - imidazol - 1 - il) - 3 - (trifluoro-metil) - fenil] - benzamida.
EP2626355B1 (en) * 2012-02-09 2016-02-03 Natco Pharma Limited Process for the preparation of nilotinib hydrochloride
GB2514285B (en) 2012-02-13 2018-07-18 Grindeks Jsc Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
EP2872142A1 (en) 2012-07-11 2015-05-20 Novartis AG Method of treating gastrointestinal stromal tumors
AU2013332205B2 (en) * 2012-10-15 2017-08-31 Apotex Inc. Solid forms of Nilotinib hydrochloride
JP2015534967A (ja) * 2012-10-19 2015-12-07 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ニロチニブと選択された共結晶体を含有する多成分結晶系
KR101858913B1 (ko) * 2013-02-21 2018-05-16 화이자 인코포레이티드 고체 형태의 선택적인 cdk4/6 억제제
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
WO2014174456A2 (en) 2013-04-24 2014-10-30 Dr. Reddys Laboratories Limited Polymorphic forms of nilotinib hydrochloride
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
WO2016020891A1 (en) 2014-08-08 2016-02-11 Dr. Reddy’S Laboratories Limited Process for the preparation of polymorphic forms of nilotinib
US10016423B2 (en) * 2014-10-16 2018-07-10 Apotex Inc. Solid forms of nilotinib hydrochloride
WO2017129694A1 (en) 2016-01-26 2017-08-03 Farma Grs, D.O.O. Nilotinib dinitrate (v) and crystalline forms thereof
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
WO2017160703A1 (en) 2016-03-14 2017-09-21 Pliva Hrvatska D.O.O. Solid state forms of nilotinib salts
CN106496193A (zh) * 2016-09-13 2017-03-15 福格森（武汉）生物科技股份有限公司 一种高纯度尼罗替尼的制备方法
EP3404025B1 (en) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
CN115569137A (zh) 2018-06-15 2023-01-06 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法
US12065426B2 (en) 2018-11-05 2024-08-20 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
AU2021212258A1 (en) 2020-01-31 2022-09-29 Flex Pharma, Llc Amorphous nilotinib microparticles and uses thereof
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
AU2021353684A1 (en) 2020-09-29 2023-06-08 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
AU2022292092A1 (en) 2021-06-19 2024-02-01 Helm Pharmaceuticals Gmbh Granulate composition comprising nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
CN113788817A (zh) * 2021-09-27 2021-12-14 南京海润医药有限公司 一种尼罗替尼半盐酸盐一水合物晶型及其制备方法
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
CN116102540B (zh) * 2023-01-05 2025-03-25 浙江工业大学 两种尼洛替尼游离碱新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701406A (en) 1901-07-16 1902-06-03 Thomas K Jones Cut-off-valve mechanism.
US701405A (en) 1902-02-17 1902-06-03 Archibald White Maconochie Ejecting device for stamping-machines.
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
BRPI0416680A (pt) * 2003-11-18 2007-02-13 Novartis Ag inibidores da forma mutante de kit
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida

Also Published As

Publication number Publication date
EA016856B1 (ru) 2012-08-30
US20130023548A1 (en) 2013-01-24
UA94234C2 (uk) 2011-04-26
GEP20115302B (en) 2011-10-10
AU2011202047A1 (en) 2011-05-26
AU2012201453A1 (en) 2012-04-05
US20130165465A1 (en) 2013-06-27
KR20130085444A (ko) 2013-07-29
AU2006276204A1 (en) 2007-02-08
CA2614334C (en) 2015-04-21
EP2535337B1 (en) 2017-08-23
EP2284167B1 (en) 2017-02-01
MX2008000899A (es) 2008-03-18
HK1116783A1 (en) 2009-01-02
NO20080820L (no) 2008-04-15
GT200600315A (es) 2007-03-19
SG163620A1 (en) 2010-08-30
ES2648288T3 (es) 2017-12-29
MY148554A (en) 2013-04-30
JP2013018789A (ja) 2013-01-31
EP1912973B1 (en) 2012-06-13
PL1912973T3 (pl) 2012-09-28
US20080269269A1 (en) 2008-10-30
HRP20170634T4 (hr) 2020-02-07
NO341930B1 (no) 2018-02-19
PH12013501590A1 (en) 2015-09-21
EP2284167A3 (en) 2011-03-02
EA200800201A1 (ru) 2008-06-30
TW200740793A (en) 2007-11-01
EP2284167A2 (en) 2011-02-16
US8415363B2 (en) 2013-04-09
SI2284167T2 (sl) 2020-03-31
RS55929B1 (sr) 2017-09-29
ES2623608T3 (es) 2017-07-11
DK2284167T4 (da) 2020-03-02
EP2543665A3 (en) 2013-05-29
MA29626B1 (fr) 2008-07-01
EP2543665A2 (en) 2013-01-09
SI1912973T1 (sl) 2012-08-31
EP2284168A3 (en) 2011-04-13
PT2284167T (pt) 2017-05-15
US20140343087A1 (en) 2014-11-20
EP2535337A1 (en) 2012-12-19
CR9657A (es) 2008-04-16
CN102358736A (zh) 2012-02-22
AR054846A1 (es) 2007-07-18
JP2009502795A (ja) 2009-01-29
US8829015B2 (en) 2014-09-09
PT1912973E (pt) 2012-09-03
KR20080027853A (ko) 2008-03-28
AU2012201453C1 (en) 2024-05-23
CN103804356A (zh) 2014-05-21
EP2284168A2 (en) 2011-02-16
DK1912973T3 (da) 2012-07-23
BRPI0613615B1 (pt) 2022-02-08
EA013464B1 (ru) 2010-04-30
TWI406661B (zh) 2013-09-01
HN2008000311A (es) 2011-01-24
AU2012201453B2 (en) 2013-09-05
IL188189A0 (en) 2008-03-20
CY1119624T1 (el) 2018-04-04
CU23916B1 (es) 2013-07-31
CA2614334A1 (en) 2007-02-08
SMAP200800011A (it) 2008-02-27
LT2284167T (lt) 2017-04-25
EA201000145A1 (ru) 2010-06-30
JP2014221831A (ja) 2014-11-27
WO2007015870A3 (en) 2007-06-07
SMP200800011B (it) 2008-02-27
CU20080006A7 (es) 2011-02-24
PE20070214A1 (es) 2007-04-02
ECSP088119A (es) 2008-02-20
BRPI0613615A2 (pt) 2011-01-18
HUE031791T2 (en) 2017-08-28
CY1113076T1 (el) 2016-04-13
JP5289948B2 (ja) 2013-09-11
RS55929B2 (sr) 2020-12-31
PL2284167T5 (pl) 2020-07-27
JP5798101B2 (ja) 2015-10-21
NZ564409A (en) 2011-07-29
WO2007015870A2 (en) 2007-02-08
HRP20170634T1 (hr) 2017-06-30
SI2284167T1 (sl) 2017-05-31
ES2623608T5 (es) 2020-06-18
US8343984B2 (en) 2013-01-01
EP1912973A2 (en) 2008-04-23
HRP20120573T1 (hr) 2012-08-31
ES2386974T3 (es) 2012-09-10
IL214659A0 (en) 2011-09-27
EP2284167B2 (en) 2019-11-27
PL2284167T3 (pl) 2017-07-31
DK2284167T3 (en) 2017-05-01
KR101651288B1 (ko) 2016-08-25
KR20130077915A (ko) 2013-07-09
TNSN08029A1 (en) 2009-07-14
JO3308B1 (ar) 2018-09-16

Similar Documents

Publication Publication Date Title
NI200800017A (es) Formas cristalinas de la 4- metil-n-[3-(4- metil- imidazol-1-il)-5- trifluoro- metil-fenil]-3- (4- piridin- 3- il- pirimidin- 2-il -amino) benzamida
ECSP088118A (es) Sales de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
UY3493Q (es) Esponja
DE602006010546D1 (de) N-(pyridin-2-yl)sulfonamidderivate
ATE471324T1 (de) Triazolophthalazine
CL2011003138A1 (es) N-(protegido- n-(3-metoxi-5-metilpirazon-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridino-3-sulfonamida y su proceso de preparacion.
NO20081292L (no) Pentasykliske kinaseinhibitorer
DE602005018653D1 (de) Aktive auswahl der bestätigungsquelle
EA201270630A1 (ru) Гетероциклические сетр ингибиторы
HRP20110093T4 (hr) Kristalna baza escitaloprama i orodisperzibilne tablete koje sadrže bazu escitaloprama
CY1110942T1 (el) Αλας αιθανολαμινης n-(3-μεθοξυ-αιθοξυ-5-μεθυλπυραζιν-2-υλ)-2-(4-[1,3,4-οξαδιαζολο -2-υλ]φαινυλ)πυριδινο-3-σουλφοναμιδιου
CU20120123A7 (es) Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-il-pirimidin-2-il-amino)-benzamida
EA200701626A1 (ru) Новые 6-пиридилфенантридины
RU2004132147A (ru) Адаптоген
RU2008127281A (ru) Производные нетропсина, обладающие антивирусной активностью
UY29682A1 (es) Formas cristalinas de 4-metil-n-(3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil)-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
ES1058748Y (es) Calendario.
UA3387U (uk) Застосування 2-феніл-3-карбетокси-4-диметиламінометил-5-оксибензофурану гідрохлориду (вінборону) як утеролітичного засобу
CL2010000211A1 (es) Formas cristalinas de sal clorhidrato 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil fenil]-3-4-piridin-3-il-pirimidin-2-ilamino)-benzamida; composicion farmaceutica que las comprende; utiles para tratar enfermedades que responden a la inhibicion de proteina quinasa.
UY3515Q (es) Parte superior inhalador-rotahaler-m-top
RU2008116394A (ru) [n-(2-гидроксиэтил)-2-аминоэтил]-3-гидрокси-4-метилсульфонил-5-(4-диметиламинофенил)-3-пирролин-2-он, проявляющий гемостатическую активность
ITPN20050026U1 (it) "piano di cottura con piastre concave"